Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: An early predictor marker of response?

Francesco Puppo, Antonino Picciotto, Sabrina Brenci, Giuseppe Varagona, Marco Scudeletti, Massimo Ghio, Vincenzo Balestra, Guido Celle, Francesco Indiveri

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Soluble HLA class I antigens (sHLA-I), β2-microglobulin (β2-μ.) and alanine aminotransferase (ALT) serum levels have been evaluated in 16 patients affected by chronic hepatitis C treated for six months with recombinant interferon-α (rIFN-α, 3 MU three times a week). The predictor role of sHLA-I and ALT modifications with respect to the response to rIFN-α therapy was also evaluated. Six patients responded (group 1), five patients relapsed following an initial response (group 2), and five did not respond to rIFN-α treatment (group 3). The baseline serum levels of sHLA-I and β2-μ were significantly higher in all three groups of HCV-positive patients with respect to HCV-negative controls (P2-μ serum levels were detected throughout the observation period. In group 1 patients ALT serum levels significantly decreased after two weeks of rIFN-α treatment (P2-μ serum levels were found during and after rIFN-α therapy. The modifications of sHLA-I serum levels discriminate, as a single marker, group 1 patients from group 2 and 3 patients after two weeks of rIFN-α treatment (P

Original languageEnglish
Pages (from-to)179-184
Number of pages6
JournalJournal of Clinical Immunology
Volume15
Issue number4
DOIs
Publication statusPublished - Jul 1995

Fingerprint

Histocompatibility Antigens Class I
Chronic Hepatitis C
HLA Antigens
Interferons
Serum
Alanine Transaminase
Therapeutics
Observation

Keywords

  • ALT
  • anti-HCV
  • Chronic active hepatitis
  • interferon-α
  • soluble HLA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy : An early predictor marker of response? / Puppo, Francesco; Picciotto, Antonino; Brenci, Sabrina; Varagona, Giuseppe; Scudeletti, Marco; Ghio, Massimo; Balestra, Vincenzo; Celle, Guido; Indiveri, Francesco.

In: Journal of Clinical Immunology, Vol. 15, No. 4, 07.1995, p. 179-184.

Research output: Contribution to journalArticle

Puppo, F, Picciotto, A, Brenci, S, Varagona, G, Scudeletti, M, Ghio, M, Balestra, V, Celle, G & Indiveri, F 1995, 'Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: An early predictor marker of response?', Journal of Clinical Immunology, vol. 15, no. 4, pp. 179-184. https://doi.org/10.1007/BF01541087
Puppo, Francesco ; Picciotto, Antonino ; Brenci, Sabrina ; Varagona, Giuseppe ; Scudeletti, Marco ; Ghio, Massimo ; Balestra, Vincenzo ; Celle, Guido ; Indiveri, Francesco. / Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy : An early predictor marker of response?. In: Journal of Clinical Immunology. 1995 ; Vol. 15, No. 4. pp. 179-184.
@article{e573850189914e4a80f35d9fc3c18dd4,
title = "Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: An early predictor marker of response?",
abstract = "Soluble HLA class I antigens (sHLA-I), β2-microglobulin (β2-μ.) and alanine aminotransferase (ALT) serum levels have been evaluated in 16 patients affected by chronic hepatitis C treated for six months with recombinant interferon-α (rIFN-α, 3 MU three times a week). The predictor role of sHLA-I and ALT modifications with respect to the response to rIFN-α therapy was also evaluated. Six patients responded (group 1), five patients relapsed following an initial response (group 2), and five did not respond to rIFN-α treatment (group 3). The baseline serum levels of sHLA-I and β2-μ were significantly higher in all three groups of HCV-positive patients with respect to HCV-negative controls (P2-μ serum levels were detected throughout the observation period. In group 1 patients ALT serum levels significantly decreased after two weeks of rIFN-α treatment (P2-μ serum levels were found during and after rIFN-α therapy. The modifications of sHLA-I serum levels discriminate, as a single marker, group 1 patients from group 2 and 3 patients after two weeks of rIFN-α treatment (P",
keywords = "ALT, anti-HCV, Chronic active hepatitis, interferon-α, soluble HLA",
author = "Francesco Puppo and Antonino Picciotto and Sabrina Brenci and Giuseppe Varagona and Marco Scudeletti and Massimo Ghio and Vincenzo Balestra and Guido Celle and Francesco Indiveri",
year = "1995",
month = "7",
doi = "10.1007/BF01541087",
language = "English",
volume = "15",
pages = "179--184",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy

T2 - An early predictor marker of response?

AU - Puppo, Francesco

AU - Picciotto, Antonino

AU - Brenci, Sabrina

AU - Varagona, Giuseppe

AU - Scudeletti, Marco

AU - Ghio, Massimo

AU - Balestra, Vincenzo

AU - Celle, Guido

AU - Indiveri, Francesco

PY - 1995/7

Y1 - 1995/7

N2 - Soluble HLA class I antigens (sHLA-I), β2-microglobulin (β2-μ.) and alanine aminotransferase (ALT) serum levels have been evaluated in 16 patients affected by chronic hepatitis C treated for six months with recombinant interferon-α (rIFN-α, 3 MU three times a week). The predictor role of sHLA-I and ALT modifications with respect to the response to rIFN-α therapy was also evaluated. Six patients responded (group 1), five patients relapsed following an initial response (group 2), and five did not respond to rIFN-α treatment (group 3). The baseline serum levels of sHLA-I and β2-μ were significantly higher in all three groups of HCV-positive patients with respect to HCV-negative controls (P2-μ serum levels were detected throughout the observation period. In group 1 patients ALT serum levels significantly decreased after two weeks of rIFN-α treatment (P2-μ serum levels were found during and after rIFN-α therapy. The modifications of sHLA-I serum levels discriminate, as a single marker, group 1 patients from group 2 and 3 patients after two weeks of rIFN-α treatment (P

AB - Soluble HLA class I antigens (sHLA-I), β2-microglobulin (β2-μ.) and alanine aminotransferase (ALT) serum levels have been evaluated in 16 patients affected by chronic hepatitis C treated for six months with recombinant interferon-α (rIFN-α, 3 MU three times a week). The predictor role of sHLA-I and ALT modifications with respect to the response to rIFN-α therapy was also evaluated. Six patients responded (group 1), five patients relapsed following an initial response (group 2), and five did not respond to rIFN-α treatment (group 3). The baseline serum levels of sHLA-I and β2-μ were significantly higher in all three groups of HCV-positive patients with respect to HCV-negative controls (P2-μ serum levels were detected throughout the observation period. In group 1 patients ALT serum levels significantly decreased after two weeks of rIFN-α treatment (P2-μ serum levels were found during and after rIFN-α therapy. The modifications of sHLA-I serum levels discriminate, as a single marker, group 1 patients from group 2 and 3 patients after two weeks of rIFN-α treatment (P

KW - ALT

KW - anti-HCV

KW - Chronic active hepatitis

KW - interferon-α

KW - soluble HLA

UR - http://www.scopus.com/inward/record.url?scp=0029151317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029151317&partnerID=8YFLogxK

U2 - 10.1007/BF01541087

DO - 10.1007/BF01541087

M3 - Article

C2 - 7593464

AN - SCOPUS:0029151317

VL - 15

SP - 179

EP - 184

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 4

ER -